Cancer clinical trials in the region Auvergne-Rhône-Alpes
498 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lung cancer
#NCT06855771
#2024-519814-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Bristol-Myers Squibb
Phase 2
Thyroid and adrenal gland cancer
#NCT03732495
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Poorly differentiated carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Radioactive iodine
Required radioactive iodine status
Resistant to radioactive iodine
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
14 recruiting sites
Centre Léon Bérard
Phase 2
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 2
Breast cancer
#NCT07405801
#2025-523013-28-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
PIK3CA
5 recruiting sites
Hoffmann-La Roche
Phase 2
Pancreas cancer
Liver and bile duct cancer
Stomach and esophageal cancer
Sarcoma and GIST
Small intestine and appendix cancer
#NCT06333314
#2023-505298-34-00
Required histologic types
Stomach
Oesogastric junction
Soft tissue sarcoma
Required histologic sub types
Adenocarcinoma
Ampullary carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1)
CPS Positive (1 <= X < 5)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Radiotherapy
7 recruiting sites
UNICANCER
Phase 2
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Stomach and esophageal cancer
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT06333314
#2023-505298-34-00
Required histologic sub types
Neuroendocrine carcinoma
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Radiotherapy
7 recruiting sites
UNICANCER
Phase 2
Acute leukemia
#NCT07007052
#2024-511003-42-00
Required histologic types
Blastic plasmacytoid dendritic cell neoplasm (BPDC...
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
9 recruiting sites
French Innovative Leukemia Organisation (FILO)
Phase 2
Lung cancer
#NCT07221474
#2025-520902-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05980806
#2024-511309-47-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Targeted therapy
8 recruiting sites
Karyopharm Therapeutics Inc.
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05037760
#2023-507468-38-00
Bras 1B et 2B
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Takeda